We investigated changes in the renin-angiotensin-aldosterone system in seven patients with essential hypertension during treatment with captopril (SQ 14225) (300 to 450 mg/day) for 12 months. While blood pressure decreased, the plasma-renin concentration increased to 700 percent of the initial value (6.1 +/- 2.5 ng angiotensin l/ml . h) and angiotensin I increased to about 300 percent of the basal value (179 +/- 32 pg/ml). Converting enzyme inhibition resulted in a 30 percent decrease in plasma angiotension II levels from a basal level of 66 +/- 21 pg/ml. Plasma aldosterone decreased 52 percent from 63 +/- 13 pg/ml initially. These changes in hormone levels were maintained throughout the study. There was no significant change in serum sodium and serum potassium concentration.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0002-9149(82)90388-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
High-Sensitive Cardiac Troponin I and Th1/Th2 Polarization in Queens With Pyometra.
Vet Med Sci
January 2025
Faculty of Veterinary Medicine, Department of Obstetrics and Gynecology, Firat University, Elazig, Turkey.
Objectives: To determine T helper (Th)1 and Th2 cytokine polarization, as well as high-sensitive cardiac troponin I (hs-cTnI) levels, in cats with pyometra.
Methods: We used 40 queens in the study. A total of 20 out of these 40 queens were diagnosed with the pyometra group (PYO) and the other 20 made up the healthy group (control; CTR).
Epigenetic Inhibitors Differentially Impact TGF-β1 Signaling Cascades in COPD Airway Smooth Muscle Cells.
Cells
December 2024
School of Life Science, University of Technology Sydney, Ultimo, NSW 2007, Australia.
Chronic obstructive pulmonary disease (COPD) is characterized by progressive and incurable airflow obstruction and chronic inflammation. Both TGF-β1 and CXCL8 have been well described as fundamental to COPD progression. DNA methylation and histone acetylation, which are well-understood epigenetic mechanisms regulating gene expression, are associated with COPD progression.
View Article and Find Full Text PDFAtypical Presentation of Andersen-Tawil Syndrome: Heart Failure with Reduced Ejection without Periodic Paralysis or Dysmorphic Features.
Eur J Case Rep Intern Med
December 2024
Internal Medicine, Holy Family Hospital, Rawalpindi, Pakistan.
Background: Andersen-Tawil syndrome (ATS) is a rare autosomal dominant disorder caused by variants in the gene. It is associated with periodic paralysis, dysmorphic features and cardiac arrhythmias. The syndrome exhibits incomplete penetrance, leading to a broad spectrum of clinical manifestations, making diagnosis challenging.
View Article and Find Full Text PDFBioequivalence Study of 2 Formulations of Fluticasone Nasal Spray in Healthy Chinese Volunteers.
Clin Pharmacol Drug Dev
January 2025
Department of Clinical Pharmacology, Aerospace Center Hospital, Beijing, China.
This study aimed to evaluate the pharmacokinetic characteristics, safety, and bioequivalence of 2 formulations of fluticasone nasal spray in healthy Chinese subjects. A single-center, randomized, open-label, single-dose, 2-formulation, 2-sequence, 2-period crossover bioequivalence study was conducted under fasting conditions. A total of 120 healthy male and female subjects were enrolled, of which 119 subjects completed the entire study.
View Article and Find Full Text PDFEfficacy of tranilast in preventing exacerbating cardiac function and death from heart failure in muscular dystrophy patients with advanced-stage heart failure: a single-arm, open-label, multicenter study.
Orphanet J Rare Dis
January 2025
Department of Cardiac Physiology, National Cerebral and Cardiovascular Center Research Institute, 6-1 Kishibe-Shimmachi, Suita, Osaka, 564-8565, Japan.
Background: Transient receptor potential cation channel subfamily V member 2 (TRPV2) functions as a stretch-sensitive calcium channel, with overexpression in the sarcolemma of skeletal and cardiac myocytes leading to detrimental calcium influx and triggering muscle degeneration. In our previous pilot study, we showed that tranilast, a TRPV2 inhibitor, reduced brain natriuretic peptide levels in two patients with muscular dystrophy and advanced heart failure. Building on this, we performed a single-arm, open-label, multicenter study herein to evaluate the safety and efficacy of tranilast in the treatment of advanced heart failure in patients with muscular dystrophy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!